Genfit S.A. (GNFT.PA)

3.81 €

+0.06 (+1.60%)
Rating:
Recommendation:
-
Symbol GNFT.PA
Price 3.81 €
Beta 1.027
Volume Avg. 0.07M
Market Cap 189.797M
Shares () -
52 Week Range 2.804-4.768
1y Target Est -
DCF Unlevered GNFT.PA DCF ->
DCF Levered GNFT.PA LDCF ->
ROE -112.38% Strong Sell
ROA -29.00% Sell
Operating Margin -
Debt / Equity 117.15% Buy
P/E 4.54 Buy
P/B 1.29 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Pascal Prigent
Healthcare
Biotechnology
Paris

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.